[Cardiological use of mononitrates].
The study has provided strong evidence for the marked antihypertensive and antiischemic effects of isosorbide-5-mononitrate (I-5-M)--the drug Monochinque retard, 50 mg (A Monarini Group, Berlin Chemie). It contributed to the reduction of the number of anginal attacks and to the alleviation of myocardial ischemia, as evidenced by Holter monitoring. The findings also indicate that there are positive changes in central hemodynamic parameters, such as left ventricular systolic and diastolic functions when Monochinque was given. The data presented suggest that Monochinque, 50 mg, an I-5-M has a positive effect on the clinical manifestations of pain and painless forms of coronary heart disease and that it alleviated functional classes II-IV heart failure.
Gurevich
M A
MA
Sanina
N P
NP
Buval'tsev
V I
VI
D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D015716:Electrocardiography, Ambulatory / Q000379:methods; D006331:Heart Diseases / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007548:Isosorbide Dinitrate / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*
D014665:Vasodilator Agents; D007548:Isosorbide Dinitrate; C030397:isosorbide-5-mononitrate